Silvia Gress

Silvia Gress

Auto-generated profile, based on publicly available information

Silvia Gress

Center of Experimental Research, Hospital de Clínicas de Porto Alegre 1 Laboratory of Genomic Medicine Porto Alegre

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
RSRenan César Sbruzzi
Renan César Sbruzzi
AGAdrian Gervais
Adrian Gervais
ESEduarda Sgarioni
Eduarda Sgarioni
SGSilvia Gress
Silvia Gress
HLHelena Suñé Lehmen
Helena Suñé Lehmen
FVFernanda SL Vianna
Fernanda SL Vianna
Inborn errors of type I IFN (IFN-I) immunity and neutralizing autoantibodies (auto-Abs) against IFN-I (AAN-I-IFNs) impair antiviral immunity and underlie critical COVID-19. Their impact on disease severity in different populations, such as Latin American populations, remains to be better understood. This study assessed the presence of AAN-I-IFNs (anti–IFN-α2, anti–IFN-ω, and anti–IFN-β) in a cohort of 458 COVID-19 patients from southern Brazil, stratified as mild (n = 224) versus non-mild (n = 234), or survivors (n = 369) versus deceased (n = 89). AAN-I-IFNs were detected in 17 patients (3.7%), with increasing prevalence across disease severity, present in one (0.4%) mild case and 16 (6.8%) hospitalized cases (P = 0.006); and eight (2.2%) survivors and nine (10.1%) deceased cases (P = 0.008). Anti–IFN-α2 and anti–IFN-ω auto-Abs were most frequently detected, while anti–IFN-β auto-Abs were found in one patient. Our findings highlight the role of AAN-I-IFNs underlying COVID-19 severity in a southern Brazilian population.